Home Alzheimer’s Disease FDA Approves Selpercatinib for 3 RET-Positive Cancer Types

FDA Approves Selpercatinib for 3 RET-Positive Cancer Types

The FDA approved selpercatinib (Retevmo), the first of its kind, to treat non-small cell lung cancer (NSCLC), medullary thyroid cancer and other types of thyroid cancers with rearranged during transfection, or RET, alterations.

Selpercatinib is indicated for the following:
• NSCLC that has spread in adults
• Advanced medullary thyroid cancer (MTC) or MTC that has spread, in patients 12 and older who require systemic therapy
• Advanced RET fusion-positive thyroid cancer in patients aged 12 and older that requires systemic therapy that has stopped responding to radioactive iodine therapy or is not appropriate for radioactive iodine therapy

The FDA made its decision based on results from a trial that evaluated the agent in 105 adult patients with RET fusion-positive NSCLC who were previously treated with platinum chemotherapy; 143 patients with advanced or metastatic RET-mutant MTC…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments